Agios, CStone to pursue ivosidenib development
CAMBRIDGE, Mass. & SUZHOU, China—An exclusive collaboration and license agreement is underway between Agios Pharmaceuticals Inc. and CStone Pharmaceuticals to develop and commercialize Agios’ ivosidenib as a monotherapy or in combination with other therapies in mainland China, Hong Kong, Macau and Taiwan. CStone will be in charge of development and commercialization activities and costs in hematologic and solid tumor indications in the given areas and will focus on acute myeloid leukemia and cholangiocarcinoma initially. Agios will retain all rights to the compound outside of the allotted territories. CStone will pay Agios $12 million up front, with the potential for up to $412 million in future milestone payments. Of that sum, $147 million is tied to development and regulatory milestones, and the other $265 million is tied to sales milestones. Agios also stands to receive tiered royalties from mid to high teens on net sales of ivosidenib.